Giliad Sciences Articles
Gilead files patent infringement suit against Lupin over Ranexa; Mylan’s generic nabumetone cleared by FDA
16 July 2010
Batch of positive opinions from Europe's Committee for Medicinal Products for Human Use recent meetings
28 June 2010
Biotech - the battle of branded drugs and generics
28 June 2010
Gilead Sciences to freeze and lower HIV drug prices to support AIDS Drug Assistance Programs
7 June 2010
Three novel HIV products from Gilead and Tibotec will earn combined peak year sales of over $5 billion
3 June 2010
J&J posts higher first-quarter 2010 profit, boosted by one-time gain, but lowers forecast; updates on Truvada combo n HIV
21 April 2010
US FDA approves Boehringer Ingelheim’s once-daily Mirapex ER for early Parkinson's disease and Gilead’s Cayston for cystic fibrosis
23 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
FDA advisory committee backs safety and efficacy of Gilead’s aztreonam for cystic fibrosis
11 December 2009
Gilead and GlaxoSmithKline to commercialize Viread for chronic hepatitis B in key Asian countries; update on Avodart
26 November 2009
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Conditional EU Marketing Authorization for Gilead’s Cayston
24 September 2009
Mylan's Matrix gets tentative FDA approval under PEPFAR for generic Atripla HIV Treatment
19 August 2009
Gilead files 2nd patent suit against Teva
15 May 2009
Gilead set to benefit from Tamiflu orders
1 May 2009
Profit up 22% at Gilead on pipeline strength
27 April 2009
Gilead completes CV Thera acquisition
21 April 2009
Achillion granted US patent for NS4A antagonist in hep C
17 April 2009
Gilead completes CV Thera tender offer
15 April 2009
Teva files ANDA on Gilead
7 April 2009
Gilead progresses on CV Thera buy
2 April 2009
Gilead begins enrolling into Ph II trial of cicletanine
30 March 2009
Gilead falls 2.4% as CHMP rejects CF drug
30 March 2009
Japan stock market week to March 16, 2009
23 March 2009
US DoJ declines to intervene in Gilead law suits
23 March 2009
Gilead to acquire CV Thera for $1.4B
16 March 2009
FDA reiterates position on Gilead response
23 February 2009
Gilead presents HIV drug-booster at CROI
16 February 2009
China imports two branded ARVs
26 January 2009
Gilead files patent suit against Teva
22 December 2008
Teva challenges two of Gilead's Truvada patents
24 November 2008
Viread suppresses HBV through 96 weeks
10 November 2008
Stock Commentary - New York week to Oct 20, 2008
27 October 2008
Gilead up almost 30% on HIV franchise
27 October 2008
Gilead names Seigo Izumo as SVP, CV unit
22 September 2008
FDA asks Gilead for another clinical study of aztreonam
22 September 2008
Stock Commentary - New York week to Sept 8, 2008
15 September 2008
US FDA approves Gilead's Viread chronic HBV infection
18 August 2008
Gilead leads in selling Atripla in new countries
11 August 2008
Gilead recruits for Ph III elvitegravir HIV trial
4 August 2008
Gilead profits up 9% on HIV franchise sales
28 July 2008
HIV/AIDS drug prices frozen for US agencies
9 June 2008
Gilead acquires Navitas' cicletanine assets
9 June 2008
Strong Ph III data for Gilead's Viread
5 May 2008
Robin Washington joins Gilead Sciences
28 April 2008
Brazil to bypass patent for ARV drug Viread
28 April 2008
Gilead record sales push revenue up 22%
28 April 2008
Gilead recruits regional general managers
7 April 2008
India NGOs at war with cancer drug patents
7 April 2008
Gilead files MAA for aztreonam nebulizer
17 March 2008
Gilead plans $500M share repurchase
10 March 2008
Gilead's sales up 40%; Viread patent challenge
4 February 2008
EC approves B-MS/Gilead's Atripla
24 December 2007
HIV/AIDS drug Atripla debuts in UK
24 December 2007
First generic Viread cleared by FDA
24 December 2007
Cipla ARV price cut does not appease campaigners
24 December 2007
Gilead submits inhalable aztreonam NDA
26 November 2007
Better 48-week efficacy with Viread vs Hepsera
21 November 2007
Stock Commentary - New York week to Nov 12, 2007
19 November 2007
Stock Commentary - New York week to Oct 29, 2007
5 November 2007
Less side effects with switch from Combivir to Truvada
5 November 2007
Gilead announces $3 billion share buyback
29 October 2007
Gilead's 3rd-qtr 2007 revenue jumps 41%
29 October 2007
Atripla approved in Canada for HIV-1
22 October 2007
Merck & Co's Cancidas comparable to AmBisome in IFI
1 October 2007
AHF blames drug firms for slow ARV uptake
24 September 2007
Small number of combination drugs reaching the Japanese market
24 September 2007
India's Cipla pricing claims disputed
3 September 2007
India's regulators investigate Cipla pricing claims
3 September 2007
Parion licenses its ENaC inhibitor to Gilead in deal worth up to $164M, gets $5M up front
3 September 2007
Truvada/Sustiva cuts viral load vs Combivir/Sustiva
6 August 2007
William Freytag joins Aspreva as chairman and CEO
16 July 2007
- Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx
- GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
- Wyeth/Pfizer accused of using ghostwritten articles to overstate benefits of HRT
- China’s liver cancer drug market forecast to nearly triple to $144 million in 2014
- International sales rep quality survey views BRIC markets
